Skip to main content

UroGen Pharma

UroGen Pharma Ltd is a clinical-stage biopharmaceutical enterprise headquartered in Princeton, New Jersey. The company focuses on the development and commercialization of innovative therapies for urological cancers and conditions. Its proprietary RTGel technology platform enables the sustained release of pharmaceutical compounds directly into the urinary tract. Principal revenue is derived through commercial pharmaceutical sales and research collaboration agreements. UroGen Pharma Ltd is publicly listed on the Nasdaq Stock Market.

4 of the funds FundTelligence covers report a position in UroGen Pharma.

Legal name
UroGen Pharma Ltd
Sector
Health Care
Country
United States
Funds holding it
4

Funds holding UroGen Pharma

Loading...